翰宇药业：预计2025年净利润为4000万元–5000万元，同比扭亏为盈

Core Viewpoint - The company expects a net profit of 40 million to 50 million yuan for the year 2025, marking a turnaround from losses to profitability [1] Group 1: Financial Performance - The company anticipates a significant improvement in net profit attributable to shareholders, achieving a turnaround from losses [1] - The expected net profit for 2025 represents a substantial increase compared to previous years [1] Group 2: Business Drivers - The primary drivers for this turnaround include a substantial increase in the scale of GLP-1 formulations and raw material business [1] - The advancement of the CRDMO (Contract Research, Development, and Manufacturing Organization) business is also contributing to the company's growth [1] Group 3: R&D Investment - The company is increasing its investment in research and development, particularly in innovative drugs like HY3003, to enhance the competitiveness of its core products [1]